<DOC>
	<DOCNO>NCT02240524</DOCNO>
	<brief_summary>The purpose study study efficacy hyperthermic intraperitoneal chemotherapy treatment patient locally advanced gastric cancer radical gastrectomy D2 lymphadenectomy . It multicentric randomised phase III trial .</brief_summary>
	<brief_title>Efficacy HIPEC Treatment Patients With Locally Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>18 &lt; age ≤ 65 year old Male Non pregnant female The Eastern Cooperative Oncology Group ( ECOG ) status ≤ 2 Histologically diagnose T4 gastric adenocarcinoma ( determine data obtain endoscopic ultrasound CT scan ) Have receive cytotoxic chemotherapy , radiotherapy immunotherapy White blood cell &gt; 4,000/mm3 neutrophil ≥ 1,500/mm3 platelet ≥ 100,000/mm3 hemoglobin &gt; 9g/l Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &lt; = 2.5 time upper limit nominal ( ULN ) total bilirubin ( TBIL ) &lt; 1.5 time ULN serum creatinine &lt; 1 time ULN Having give write informed consent prior procedure relate study Existence macroscopic peritoneal implant Prior malignant tumor detectable sign recurrence distant metastasis Poorly control disease e.g . atrial fibrillation , stenocardia , cardiac insufficiency , persistent hypertension despite medicinal treatment , ejection fraction &lt; 50 % Receiving cytotoxic chemotherapy High grade intraabdominal adhesion Contraindication therapy contain regimen specific study Without give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Gastric adenocarcinoma</keyword>
	<keyword>HIPEC</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Capecitabine</keyword>
</DOC>